ReviewProstate cancer2016
Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy.
Review in Prostate cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 79 citations in OpenAlex.
- A Gene Feature Based on Histone Modifications Can Predict the Prognosis of Prostate Cancer.Biomedicines · 2026Article
- Review
- Real‑world retrospective study of early‑stage prostate cancer at a Portuguese Comprehensive Cancer Centre: The PEarlC study.Oncology letters · 2024Article
- TP63-TRIM29 axis regulates enhancer methylation and chromosomal instability in prostate cancer.Epigenetics & chromatin · 2024Article
- Review
- Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.Journal of bone and mineral metabolism · 2024Article
- Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.Cancers · 2024Review
- Article
- Exosomal miRNAs-a diagnostic biomarker acting as a guiding light in the diagnosis of prostate cancer.Functional & integrative genomics · 2022Review
- Deubiquitinase USP35 stabilizes BRPF1 to activate mevalonate (MVA) metabolism during prostate tumorigenesis.Cell death discovery · 2022Article
- Volatilomics: An Emerging and Promising Avenue for the Detection of Potential Prostate Cancer Biomarkers.Cancers · 2022Review
- Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.Signal transduction and targeted therapy · 2022Review
- Modeling and Operator Control of a Robotic Tool for Bidirectional Manipulation in Targeted Prostate Biopsy.... International Symposium on Medical Robotics. International Symposium on Medical Robotics · 2022Article
- Exercise training as a modulator of epigenetic events in prostate tumors.Prostate cancer and prostatic diseases · 2022Article
- Molecular Mechanisms of Coffee on Prostate Cancer Prevention.BioMed research international · 2022Review
- Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors.Frontiers in genetics · 2022Review
- microRNA-211-mediated targeting of the INHBA-TGF-β axis suppresses prostate tumor formation and growth.Cancer gene therapy · 2021Article
- Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.International journal of molecular sciences · 2021Review
- SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop.Cell death & disease · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is the most prevalent urological cancer that affects aging men in South Africa, and mechanisms underlying prostate tumorigenesis remain elusive. Research advancements in the field of PCa and epigenetics have allowed for the identification of specific alterations that occur beyond genetics but are still critically important in the pathogenesis of tumorigenesis. Anomalous epigenetic changes associated with PCa include histone modifications, DNA methylation, and noncoding miRNA. These mechanisms regulate and silence hundreds of target genes including some which are key components of cellular signalling pathways that, when perturbed, promote tumorigenesis. Elucidation of mechanisms underlying epigenetic alterations and the manner in which these mechanisms interact in regulating gene transcription in PCa are an unmet necessity that may lead to novel chemotherapeutic approaches. This will, therefore, aid in developing combination therapies that will target multiple epigenetic pathways, which can be used in conjunction with the current conventional PCa treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.